

Hector O Ventura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7118794/publications.pdf>

Version: 2024-02-01

324
papers

12,906
citations

30070

54
h-index

27406

106
g-index

341
all docs

341
docs citations

341
times ranked

13169
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility and Safety of Coronary Angiography via Radial Approach in Cardiac Transplant Recipients: A Single Center Experience. <i>Current Problems in Cardiology</i> , 2022, 47, 100935.	2.4	1
2	The era of heart failure risk prediction models, is it time to test their utility?. <i>International Journal of Cardiology</i> , 2022, 352, 98-99.	1.7	2
3	Understanding Heart Failure Risk in a Diverse Cohort With Human Immunodeficiency Virus Infection. <i>Mayo Clinic Proceedings</i> , 2022, 97, 433-435.	3.0	0
4	The Impact of Obesity in Heart Failure. <i>Cardiology Clinics</i> , 2022, 40, 209-218.	2.2	5
5	Emerging Comorbidities in Heart Failure. <i>Cardiology Clinics</i> , 2022, 40, xi-xiv.	2.2	0
6	Preimplant hyponatremia does not predict adverse outcomes in patient with left ventricular assist devices. <i>Current Problems in Cardiology</i> , 2022, , 101239.	2.4	0
7	Is There an Obesity Paradox in Cardiogenic Shock?. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	1
8	Laparoscopic Sleeve Gastrectomy in Patients with Obesity and Ventricular Assist Devices: a Comprehensive Outcome Analysis. <i>Obesity Surgery</i> , 2021, 31, 884-890.	2.1	10
9	Obesity Is a Heavy Load in Cardiogenic Shock and Mechanical Circulation. <i>Circulation: Heart Failure</i> , 2021, 14, e008300.	3.9	4
10	Editorial: The burden of hypertension and its management. <i>Current Opinion in Cardiology</i> , 2021, 36, 397.	1.8	0
11	Bariatric Surgery in Patients with Obesity and Ventricular Assist Devices Considered for Heart Transplantation: Systematic Review and Individual Participant Data Meta-analysis. <i>Journal of Cardiac Failure</i> , 2021, 27, 338-348.	1.7	11
12	New aspects in the management of hypertension in the digital era. <i>Current Opinion in Cardiology</i> , 2021, 36, 398-404.	1.8	4
13	Interactions of hypertension, obesity, left ventricular hypertrophy, and heart failure. <i>Current Opinion in Cardiology</i> , 2021, 36, 453-460.	1.8	15
14	Prognostic value of cardiopulmonary exercise test after heart transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14387.	1.6	3
15	Bulla hemorrÁgica rota en un paciente con un HeartMate 3 tratado con un dispositivo Amplatzer. <i>Archivos De Cardiologia De Mexico</i> , 2021, 91, .	0.2	0
16	Triple Antithrombotic Therapy in Patients With Left Ventricular Assist Devices. <i>Current Problems in Cardiology</i> , 2021, 47, 100940.	2.4	2
17	FGF23 predicts outcomes in heart failure but questions remain unanswered. <i>International Journal of Cardiology</i> , 2021, 338, 145-146.	1.7	3
18	Impact of Preinfection Left Ventricular Ejection Fraction on Outcomes in COVID-19 Infection. <i>Current Problems in Cardiology</i> , 2021, 46, 100845.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Race and Ethnicity in Heart Failure. Journal of the American College of Cardiology, 2021, 78, 2589-2598.	2.8	27
20	When good intentions turn bad: A need for course correction. Journal of Heart and Lung Transplantation, 2020, 39, 5-6.	0.6	8
21	Left ventricular hypertrophy and hypertension. Progress in Cardiovascular Diseases, 2020, 63, 10-21.	3.1	184
22	Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e265-e286.	1.6	107
23	Mechanical circulatory support devices in advanced heart failure: 2020 and beyond. Progress in Cardiovascular Diseases, 2020, 63, 630-639.	3.1	38
24	Implications of obesity across the heart failure continuum. Progress in Cardiovascular Diseases, 2020, 63, 561-569.	3.1	43
25	Effect of patiomer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. Progress in Cardiovascular Diseases, 2020, 63, 656-661.	3.1	4
26	Impact of a mentor. Progress in Cardiovascular Diseases, 2020, 63, 704-705.	3.1	0
27	Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk. Current Problems in Cardiology, 2020, 45, 100653.	2.4	2
28	Laparoscopic Sleeve Gastrectomy in Patients with Ventricular Assist Devices, Beyond Just Bridging to Heart Transplantation. Obesity Surgery, 2020, 30, 5123-5124.	2.1	2
29	Laparoscopic sleeve gastrectomy in obese patients with ventricular assist devices: a data note. BMC Research Notes, 2020, 13, 439.	1.4	0
30	BMI Trends In Patients With Ventricular Assist Devices After Bariatric Surgery. Journal of Cardiac Failure, 2020, 26, S40-S41.	1.7	0
31	Editorial: Hypertension in special populations and the role in comorbidities. Current Opinion in Cardiology, 2020, 35, 341.	1.8	0
32	We all need a yellow submarine!. Progress in Cardiovascular Diseases, 2020, 63, 389.	3.1	1
33	Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2020, 75, 255-257.	2.8	4
34	Use of TandemHeart as Bridge to Recovery for Antibody-Mediated Rejection in a Heart Transplant Patient. JACC: Case Reports, 2020, 2, 2358-2362.	0.6	0
35	Ruptured Bullae: A Rare Cause of No-flow Alarms In Ventricular Assist Devices. Journal of Cardiac Failure, 2020, 26, S62.	1.7	0
36	Outcomes After Bariatric Surgery In Patients With Ventricular Assist Devices: Systematic Review And Individual Participant Data Meta-analysis. Journal of Cardiac Failure, 2020, 26, S53.	1.7	0

#	ARTICLE	IF	CITATIONS
37	New Guidelines, Increasing Hypertension Numbers, Resistance and Resistance to Change?. Mayo Clinic Proceedings, 2019, 94, 745-747.	3.0	1
38	An update on pharmacotherapies in diabetic dyslipidemia. Progress in Cardiovascular Diseases, 2019, 62, 334-341.	3.1	24
39	Diabetic cardiomyopathy - A comprehensive updated review. Progress in Cardiovascular Diseases, 2019, 62, 315-326.	3.1	197
40	Editorial. Current Opinion in Cardiology, 2019, 34, 329-330.	1.8	5
41	Management of resistant hypertension. Current Opinion in Cardiology, 2019, 34, 367-375.	1.8	2
42	Edward D. Frohlich, MD. Hypertension, 2019, 74, 1229-1231.	2.7	0
43	HDL and Heart Failure Regulation. Journal of the American College of Cardiology, 2019, 73, 187-189.	2.8	2
44	Health Literacy: An Important Clinical Tool in Heart Failure. Mayo Clinic Proceedings, 2018, 93, 1-3.	3.0	5
45	Blood pressure and goal titration of neurohormonal antagonists: the tortoise wins again?. European Journal of Heart Failure, 2018, 20, 501-503.	7.1	0
46	Future pharmacological therapy in hypertension. Current Opinion in Cardiology, 2018, 33, 408-415.	1.8	12
47	Obesity and Prognosis in Pediatric Dilated Cardiomyopathy. JACC: Heart Failure, 2018, 6, 231-232.	4.1	1
48	Management of cardiovascular diseases in patients with obesity. Nature Reviews Cardiology, 2018, 15, 45-56.	13.7	153
49	Rehabilitating cardiac rehabilitation after heart transplantation. Journal of Heart and Lung Transplantation, 2018, 37, 437-438.	0.6	2
50	The Impact of Mediators of Health Literacy on Clinical Outcomes in Cardiovascular Diseases. Mayo Clinic Proceedings, 2018, 93, 1700-1702.	3.0	2
51	Prognostic Implications of Left Ventricular Hypertrophy. Progress in Cardiovascular Diseases, 2018, 61, 446-455.	3.1	75
52	Improving Provider Adherence to Guideline Recommendations in Heart Failure. Current Heart Failure Reports, 2018, 15, 350-356.	3.3	3
53	John Lockwood Ochsner: Celebration of life. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1769-1771.	0.8	0
54	Muscling up to improve heart failure prognosis. European Journal of Heart Failure, 2018, 20, 1588-1590.	7.1	30

#	ARTICLE	IF	CITATIONS
55	Psychopharmacology and Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 71, 2346-2359.	2.8	72
56	Hypertension. Current Opinion in Cardiology, 2018, 33, 375-376.	1.8	5
57	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. Current Problems in Cardiology, 2017, 42, 198-225.	2.4	17
58	Observations and Reflections on the Burden of Hospitalizations for Heart Failure. Mayo Clinic Proceedings, 2017, 92, 175-178.	3.0	8
59	The Interaction of Cardiorespiratory Fitness With Obesity and the Obesity Paradox in Cardiovascular Disease. Progress in Cardiovascular Diseases, 2017, 60, 30-44.	3.1	132
60	The importance of achieving blood pressure control, what is the target?. Current Opinion in Cardiology, 2017, 32, 363-364.	1.8	3
61	Observations on the blood pressure paradox in heart failure. European Journal of Heart Failure, 2017, 19, 843-845.	7.1	13
62	Therapeutic Cardiorespiratory Fitness to Prevent and Treat Heart Failure —. JACC: Heart Failure, 2017, 5, 375-376.	4.1	0
63	INFLUENCE OF LOW VERSUS HIGH DOSE ON THE ASSOCIATION OF LOOP DIURECTIC AND MORTALITY IN PATIENTS WITH HEART FAILURE: INSIGHTS FROM THE UNITE-HF REGISTRY. Journal of the American College of Cardiology, 2017, 69, 710.	2.8	0
64	Foreword. Current Problems in Cardiology, 2017, 42, 172.	2.4	0
65	Pharmacologic Therapy for Heart Failure With Reduced Ejection Fraction: Closing the Gap Between Clinical Guidelines and Practice. Progress in Cardiovascular Diseases, 2017, 60, 187-197.	3.1	14
66	Changing our Approach to Stage D Heart Failure. Progress in Cardiovascular Diseases, 2017, 60, 205-214.	3.1	9
67	Comprehensive Heart Failure Management. Progress in Cardiovascular Diseases, 2017, 60, 169-170.	3.1	3
68	Adipose Composition and Heart Failure Prognosis. Journal of the American College of Cardiology, 2017, 70, 2750-2751.	2.8	22
69	Hemodynamic effects of a fully magnetically levitated centrifugal-flow left ventricular assist device. Journal of Heart and Lung Transplantation, 2017, 36, 19-21.	0.6	0
70	Improving Hypertension Control and Patient Engagement Using Digital Tools. American Journal of Medicine, 2017, 130, 14-20.	1.5	127
71	Obesity and cardiovascular diseases. Minerva Medica, 2017, 108, 212-228.	0.9	151
72	Impact of comorbidities in hypertension. Current Opinion in Cardiology, 2016, 31, 374-375.	1.8	14

#	ARTICLE	IF	CITATIONS
73	Genotype and Phenotype of Transthyretin Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2016, 68, 161-172.	2.8	338
74	Foreword. <i>Current Problems in Cardiology</i> , 2016, 41, 249.	2.4	0
75	Foreword. <i>Current Problems in Cardiology</i> , 2016, 41, 265.	2.4	0
76	Tackling cardiovascular disease in Hispanic/Latinos: Achieving 2020 Goals. <i>American Heart Journal</i> , 2016, 176, 125-126.	2.7	1
77	Obesity Cardiomyopathy: Pathophysiologic Factors and Nosologic Reevaluation. <i>American Journal of the Medical Sciences</i> , 2016, 352, 219-222.	1.1	36
78	In Memoriam Arnold M Katz, MD. <i>American Journal of Cardiology</i> , 2016, 117, 1996-1997.	1.6	0
79	Current Perspectives on Left Ventricular Geometry in Systemic Hypertension. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 235-246.	3.1	45
80	Foreword. <i>Current Problems in Cardiology</i> , 2016, 41, 193.	2.4	1
81	New Concepts in Hypertension Management: A Population-Based Perspective. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 289-294.	3.1	19
82	Body Composition and Advanced Heart Failure Therapy. <i>JACC: Heart Failure</i> , 2016, 4, 769-771.	4.1	11
83	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1072-1081.	7.1	44
84	Body habitus in heart failure: understanding the mechanisms and clinical significance of the obesity paradox. <i>Future Cardiology</i> , 2016, 12, 639-653.	1.2	16
85	Influence of Neurohormonal Antagonists on the Association of Loop Diuretic Dose with Mortality in Patients with Heart Failure: Insights From the UNITE-HF Registry. <i>Journal of Cardiac Failure</i> , 2016, 22, S35.	1.7	1
86	Coenzyme Q10 and Utility in Heart Failure: Just Another Supplement?. <i>Current Heart Failure Reports</i> , 2016, 13, 190-195.	3.3	15
87	Impact of Obesity on the Prevalence and Prognosis of Heart Failure—It Is Not Always Just Black and White. <i>Journal of Cardiac Failure</i> , 2016, 22, 598-599.	1.7	3
88	Update on Obesity and Obesity Paradox in Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 393-400.	3.1	199
89	Reply. <i>JACC: Heart Failure</i> , 2016, 4, 234-235.	4.1	2
90	The Secret Trip of Dr Alton Ochsner. <i>Ochsner Journal</i> , 2016, 16, 116-9.	1.1	0

#	ARTICLE	IF	CITATIONS
91	Using the Minimally Invasive Impella 5.0 via the Right Subclavian Artery Cutdown for Acute on Chronic Decompensated Heart Failure as a Bridge to Decision. <i>Ochsner Journal</i> , 2016, 16, 210-6.	1.1	25
92	Breaking Down the Barriers: Why the Delay in Referral for Pulmonary Arterial Hypertension?. <i>Ochsner Journal</i> , 2016, 16, 257-62.	1.1	2
93	The Bi-directional Impact of Two Chronic Illnesses: Heart Failure and Diabetes – A review of the Epidemiology and Outcomes. <i>Cardiac Failure Review</i> , 2015, 1, 8.	3.0	22
94	The Obesity Paradox in Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 927-930.	4.1	35
95	Impact of Ethnicity and Race on Response to Angiotensin-Converting Enzyme Inhibitors in Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 457-459.	1.7	0
96	Regional differences in use and outcomes of left ventricular assist devices: Insights from the Interagency Registry for Mechanically Assisted Circulatory Support Registry. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 912-920.	0.6	12
97	Risks and Benefits of Weight Loss in Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, 125-131.	2.1	17
98	Bioethics in Practice: Quantity, but More Important, Quality of Life in Heart Failure. <i>Ochsner Journal</i> , 2015, 15, 216.	1.1	0
99	Management of Patients Admitted with Acute Decompensated Heart Failure. <i>Ochsner Journal</i> , 2015, 15, 284-9.	1.1	4
100	Disparate Effects of Metabolically Healthy Obesity in Coronary Heart Disease and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1079-1081.	2.8	23
101	Effects of Left Ventricular Geometry and Obesity on Mortality in Women With Normal Ejection Fraction. <i>American Journal of Cardiology</i> , 2014, 113, 877-880.	1.6	19
102	Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure – A Pilot Study (PRONTO). <i>American Heart Journal</i> , 2014, 167, 529-536.	2.7	80
103	Obesity Paradox, Cachexia, Frailty, and Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 319-326.	2.1	58
104	Clinical Characteristics, Treatment Patterns and Outcomes of Hispanic Hypertensive Patients. <i>Progress in Cardiovascular Diseases</i> , 2014, 57, 244-252.	3.1	10
105	A perspective on re-evaluating digoxin's role in the current management of patients with chronic systolic heart failure: targeting serum concentration to reduce hospitalization and improve safety profile. <i>European Journal of Heart Failure</i> , 2014, 16, 483-493.	7.1	28
106	The consummate clinician. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1103.	0.6	1
107	Heart Failure in Ethnic Minorities. <i>JACC: Heart Failure</i> , 2014, 2, 400-402.	4.1	4
108	Effects of Obesity and Weight Changes on Cardiac and Vascular Structure and Function. <i>JACC: Heart Failure</i> , 2014, 2, 509-511.	4.1	8

#	ARTICLE	IF	CITATIONS
109	Preface. Heart Failure Clinics, 2014, 10, xi.	2.1	1
110	Clinical Implications of Weight Loss in Heart Failure. Journal of Cardiac Failure, 2014, 20, 190-192.	1.7	6
111	Impact of Echocardiographic Left Ventricular Geometry on Clinical Prognosis. Progress in Cardiovascular Diseases, 2014, 57, 3-9.	3.1	78
112	Micronutrients in Chronic Heart Failure. Current Heart Failure Reports, 2013, 10, 46-53.	3.3	35
113	Thiamine Supplementation for the Treatment of Heart Failure: A Review of the Literature. Congestive Heart Failure, 2013, 19, 214-222.	2.0	69
114	Racial/Ethnic Differences in B-Type Natriuretic Peptide Levels and Their Association With Care and Outcomes Among Patients Hospitalized With Heart Failure. JACC: Heart Failure, 2013, 1, 345-352.	4.1	32
115	TOTAL BILIRUBIN/ALBUMIN RATIO HAS AN INDEPENDENT AND INCREMENTAL ROLE IN PREDICTING RIGHT VENTRICULAR FAILURE AFTER LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION. Journal of the American College of Cardiology, 2013, 61, E756.	2.8	1
116	Transcatheter Potts shunt: An innovative IDEA. Journal of Heart and Lung Transplantation, 2013, 32, 388-389.	0.6	1
117	Impact of Obesity and the Obesity Paradox on Prevalence and Prognosis in Heart Failure. JACC: Heart Failure, 2013, 1, 93-102.	4.1	463
118	Aldosterone Antagonists: Evidence-Based Yet Underutilized Effective Heart Failure Therapy. Congestive Heart Failure, 2013, 19, 105-106.	2.0	4
119	Fragmented QRS Complexes—A Novel but Underutilized Electrocardiographic Marker of Heart Disease. Critical Pathways in Cardiology, 2013, 12, 181-183.	0.5	14
120	Analyzing the Weight of Evidence on the Obesity Paradox and Heart Failure—Is There a Limit to the Madness?. Congestive Heart Failure, 2013, 19, 158-159.	2.0	20
121	Antihypertensive therapy versus alternative therapeutic options for prehypertension: an evidence-based approach. Future Cardiology, 2012, 8, 115-122.	1.2	6
122	Do BNP Levels and Prognostic Value Vary by Race/Ethnicity in Patients Hospitalized With Heart Failure?. Journal of Cardiac Failure, 2012, 18, S80-S81.	1.7	0
123	Exercise Training as Treatment of Depression in Heart Failure. Journal of the American College of Cardiology, 2012, 59, 291.	2.8	3
124	Association of Left Ventricular Geometry With Left Atrial Enlargement in Patients With Preserved Ejection Fraction. Congestive Heart Failure, 2012, 18, 4-8.	2.0	28
125	Developments in Heart Failure 2011. Congestive Heart Failure, 2012, 18, 112-126.	2.0	2
126	Should We Start Prescribing Omega-3 Polyunsaturated Fatty Acids in Chronic Heart Failure?. Current Heart Failure Reports, 2012, 9, 8-13.	3.3	4

#	ARTICLE	IF	CITATIONS
127	Natriuretic Peptides as Markers of Cardiovascular Risk: The Story Continues. Mayo Clinic Proceedings, 2011, 86, 1143-1145.	3.0	5
128	Left Atrial Volume Index Predictive of Mortality Independent of Left Ventricular Geometry in a Large Clinical Cohort With Preserved Ejection Fraction. Mayo Clinic Proceedings, 2011, 86, 730-737.	3.0	72
129	The Coalition to Reduce Racial and Ethnic Disparities in Cardiovascular Disease Outcomes (credo). Journal of the American College of Cardiology, 2011, 57, 245-252.	2.8	82
130	Impact of Obesity on Outcomes in Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 2651-2653.	2.8	32
131	Weighing in on Obesity and the Obesity Paradox in Heart Failure. Journal of Cardiac Failure, 2011, 17, 381-383.	1.7	19
132	Advances in mechanical circulatory support: Year in review. Journal of Heart and Lung Transplantation, 2011, 30, 487-493.	0.6	34
133	Geographic variations of acute heart failure syndromes. American Heart Journal, 2011, 162, 1-2.	2.7	13
134	Nitroprusside and the Treatment of Hypertension. Congestive Heart Failure, 2011, 17, 49-49.	2.0	2
135	Nitroprusside in Refractory Heart Failure. Congestive Heart Failure, 2011, 17, 157-157.	2.0	0
136	Relationship Between Arterial Impedance and Concentric Remodeling in Patients With Normal Systolic Function: Impact on Prevalence and Survival. Congestive Heart Failure, 2011, 17, 283-287.	2.0	1
137	Nutritional Assessment in Heart Failure Patients. Congestive Heart Failure, 2011, 17, 199-203.	2.0	25
138	Impact of Exercise Training and Depression on Survival in Heart Failure Due to Coronary Heart Disease. American Journal of Cardiology, 2011, 107, 64-68.	1.6	100
139	Kenneth Baughman, MD: A Personal Reflection. American Journal of Cardiology, 2011, 107, 139-140.	1.6	1
140	Progression from Concentric Left Ventricular Hypertrophy and Normal Ejection Fraction to Left Ventricular Dysfunction. American Journal of Cardiology, 2011, 108, 992-996.	1.6	45
141	Obesity, Age, and Cardiac Risk. Current Cardiovascular Risk Reports, 2011, 5, 128-137.	2.0	8
142	Disparities in Women with Heart Failure. Current Cardiovascular Risk Reports, 2011, 5, 261-265.	2.0	2
143	Metabolic Syndrome and Heart Failure—The Risk, Paradox, and Treatment. Current Hypertension Reports, 2011, 13, 142-148.	3.5	25
144	Antihypertensive Therapy for Prehypertension. JAMA - Journal of the American Medical Association, 2011, 305, 940.	7.4	11

#	ARTICLE	IF	CITATIONS
145	Value of Weight Reduction in Patients with Cardiovascular Disease. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 21-35.	0.9	27
146	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2010, 16, 42-43.	2.0	0
147	Induced Hypothermia Prior to Left Ventricular Assist Device. Congestive Heart Failure, 2010, 16, 231-233.	2.0	0
148	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2010, 16, 136-137.	2.0	0
149	Heart Failure in Hispanic Patients: Coming Together?. Congestive Heart Failure, 2010, 16, 187-188.	2.0	2
150	Use of Body Fatness Cutoff Pointsâ€“Replyâ€“l. Mayo Clinic Proceedings, 2010, 85, 1057-1058.	3.0	10
151	Body Composition and Heart Failure Prevalence and Prognosis: Getting to the Fat of the Matter in the â€œObesity Paradoxâ€œ. Mayo Clinic Proceedings, 2010, 85, 605-608.	3.0	87
152	New Data on the Clinical Impact of Exercise Training, Fish Oils, and Statins in Heart Failure. Physician and Sportsmedicine, 2009, 37, 22-28.	2.1	6
153	Clinical Impact of Left Ventricular Hypertrophy and Implications for Regression. Progress in Cardiovascular Diseases, 2009, 52, 153-167.	3.1	140
154	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2009, 15, 101-101.	2.0	1
155	Heart Failure and Cardiac Catheterization. Congestive Heart Failure, 2009, 15, 295-295.	2.0	0
156	Cardiac Carcinoid. Congestive Heart Failure, 2009, 15, 43-45.	2.0	0
157	Usefulness of Heart Rate as an Independent Predictor for Survival After Heart Transplantation. American Journal of Cardiology, 2009, 103, 1290-1294.	1.6	26
158	Cardiovascular Outcomes and Angiotensin Converting Enzyme Inhibitors: Beyond Blood Pressure Control. Cardiovascular Drugs and Therapy, 2009, 23, 109-111.	2.6	1
159	Exercise Training and Heart Failure in Older Adultsâ€“Dismal Failure or Not Enough Exercise?. Journal of the American Geriatrics Society, 2009, 57, 2148-2150.	2.6	0
160	High-density Lipoprotein Cholesterol Levels and Prognosis in Advanced Heart Failure. Journal of Heart and Lung Transplantation, 2009, 28, 876-880.	0.6	41
161	Baseline differences in the HF-ACTION trial by sex. American Heart Journal, 2009, 158, S16-S23.	2.7	40
162	The Obesity Paradox, Weight Loss, and Coronary Disease. American Journal of Medicine, 2009, 122, 1106-1114.	1.5	215

#	ARTICLE	IF	CITATIONS
163	Obesity and Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 53, 1925-1932.	2.8	1,759
164	Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. Journal of the American College of Cardiology, 2009, 54, 585-594.	2.8	518
165	Hypertension and Cardiac Failure in its Various Forms. Medical Clinics of North America, 2009, 93, 665-680.	2.5	30
166	Dietary intake of nuts and cardiovascular prognosis. Ochsner Journal, 2009, 9, 32-6.	1.1	6
167	Metabolic parameters derived from cardiopulmonary stress testing for prediction of prognosis in patients with heart failure: the ochsner experience. Ochsner Journal, 2009, 9, 46-53.	1.1	7
168	Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss. Ochsner Journal, 2009, 9, 124-32.	1.1	54
169	Advanced heart failure and management strategies. Ochsner Journal, 2009, 9, 227-33.	1.1	1
170	In Memoriam Charles Wooley, MD. American Journal of Cardiology, 2008, 101, 1677-1678.	1.6	0
171	Impact of Obesity on the Risk of Heart Failure and Its Prognosis. Journal of the Cardiometabolic Syndrome, 2008, 3, 155-161.	1.7	54
172	Obesity, Hypertension, and the Heart. Journal of the Cardiometabolic Syndrome, 2008, 3, 168-172.	1.7	18
173	Device Therapy for Heart Failure. American Journal of Cardiovascular Drugs, 2008, 8, 147-153.	2.2	5
174	Selling Teaching Hospitals and Practice Plans: George Washington and Georgetown Universities. JAMA - Journal of the American Medical Association, 2008, 300, 2555.	7.4	0
175	The "Obesity Paradox". Chest, 2008, 134, 896-898.	0.8	36
176	Untangling the heavy cardiovascular burden of obesity. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 428-429.	3.3	19
177	The Obesity Paradox: Impact of Obesity on the Prevalence and Prognosis of Cardiovascular Diseases. Postgraduate Medicine, 2008, 120, 34-41.	2.0	98
178	Fish oil in primary and secondary cardiovascular prevention. Ochsner Journal, 2008, 8, 49-60.	1.1	10
179	Impact of left ventricular geometry on prognosis-a review of ochsner studies. Ochsner Journal, 2008, 8, 11-7.	1.1	15
180	Pathophysiology of Pulmonary Arterial Hypertension. Seminars in Cardiothoracic and Vascular Anesthesia, 2007, 11, 104-109.	1.0	12

#	ARTICLE	IF	CITATIONS
181	Obesity, Heart Disease, and Favorable Prognosis—Truth or Paradox?. American Journal of Medicine, 2007, 120, 825-826.	1.5	52
182	Disparate Effects of Left Ventricular Geometry and Obesity on Mortality in Patients With Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology, 2007, 100, 1460-1464.	1.6	123
183	The Obesity Paradox and Discrepancy Between Peak Oxygen Consumption and Heart Failure Prognosis? It's All in the Fat. Congestive Heart Failure, 2007, 13, 177-180.	2.0	11
184	Is Heart Failure More Prevalent in Patients With Peripheral Arterial Disease? A Meta-Analysis. Congestive Heart Failure, 2007, 13, 319-322.	2.0	45
185	Dickinson Woodruff Richards and Cardiac Catheterization. Clinical Cardiology, 2007, 30, 420-421.	1.8	5
186	Henry w. Ochsner, MD - the ochsner lineage in medicine. Ochsner Journal, 2007, 7, 73.	1.1	0
187	Research at ochsner clinic: highlights in its history. Ochsner Journal, 2007, 7, 74-6.	1.1	0
188	Understanding the Basics of Cardiopulmonary Exercise Testing. Mayo Clinic Proceedings, 2006, 81, 1603-1611.	3.0	140
189	Ancient Egyptian Medicine and the Concept of Heart Failure. Journal of Cardiac Failure, 2006, 12, 416-421.	1.7	36
190	Edward D. Freis-A True Pioneer. Journal of Clinical Hypertension, 2006, 8, 284-287.	2.0	0
191	Fish Oils Produce Anti-inflammatory Effects and Improve Body Weight in Severe Heart Failure. Journal of Heart and Lung Transplantation, 2006, 25, 834-838.	0.6	106
192	Osborn Waves in Sepsis. Southern Medical Journal, 2006, 99, 1302-1303.	0.7	10
193	Hypertension and heart failure: Diagnosis and management. Current Hypertension Reports, 2006, 8, 185-190.	3.5	5
194	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2006, 12, 54-54.	2.0	0
195	Adjunctive Sildenafil for the Treatment of Pulmonary Hypertension After Mitral Valve Replacement. Congestive Heart Failure, 2006, 12, 347-348.	2.0	3
196	Left Ventricular Geometry and Survival in Patients With Normal Left Ventricular Ejection Fraction. American Journal of Cardiology, 2006, 97, 959-963.	1.6	156
197	Comparison of Cardiac and Peripheral Arterial Stiffening and Ventriculovascular Uncoupling in Patients With Uncomplicated Hypertension Versus Patients With Hypertension After Heart Transplantation. American Journal of Cardiology, 2006, 98, 789-792.	1.6	10
198	Left Ventricular Geometry and Mortality in Patients >70 Years of Age With Normal Ejection Fraction. American Journal of Cardiology, 2006, 98, 1396-1399.	1.6	68

#	ARTICLE	IF	CITATIONS
199	H.J.C. â€œJeremyâ€•Swan, MD: In memory of his contributions to cardiovascular medicine. Catheterization and Cardiovascular Interventions, 2006, 67, 171-174.	1.7	0
200	A Historical Look at Hypertension: Celebrating 100 Years with the Southern Medical Association. Southern Medical Journal, 2006, 99, 1412-1413.	0.7	2
201	Preventive cardiology and non-invasive cardiology research at the ochsner clinic foundation. Ochsner Journal, 2006, 6, 31-5.	1.1	1
202	The Interaction of Vascular Stiffness and Cardiovascular Events in Women. Chest, 2005, 127, 1477-1480.	0.8	6
203	Early recognition and treatment of hypertensive heart disease. Current Opinion in Cardiology, 2005, 20, 282-289.	1.8	17
204	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. American Journal of Cardiology, 2005, 95, 367-372.	1.6	43
205	Relation Between Left Ventricular Geometry and Transmural Dispersion of Repolarization. American Journal of Cardiology, 2005, 96, 952-955.	1.6	18
206	Relationship Among Epicardial Coronary Disease, Tissue Myocardial Perfusion, and Survival in Heart Transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 1019-1025.	0.6	26
207	Hypertension as a hemodynamic disease: The role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. American Journal of Hypertension, 2005, 18, 26-43.	2.0	70
208	Bloodletting as a Cure For Dropsy: Heart Failure Down the Ages. Journal of Cardiac Failure, 2005, 11, 247-252.	1.7	20
209	Obesity and B-type natriuretic peptide levels in heart failure: Reply. Journal of the American College of Cardiology, 2005, 45, 967.	2.8	0
210	Is It Constrictive Pericarditis or Restrictive Cardiomyopathy? A Systematic Approach. Congestive Heart Failure, 2004, 10, 309-312.	2.0	3
211	Usefulness of B-Type Natriuretic Peptide as a Predictor of Treatment Outcome in Pulmonary Arterial Hypertension. Congestive Heart Failure, 2004, 10, 221-225.	2.0	33
212	â€œRead Guytonâ€• American Journal of Cardiology, 2004, 93, 516-517.	1.6	0
213	Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. American Journal of Cardiology, 2004, 94, 454-458.	1.6	85
214	Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. American Journal of Cardiology, 2004, 94, 1475-1477.	1.6	125
215	The impact of mode of donor brain death on cardiac allograft vasculopathy. Journal of the American College of Cardiology, 2004, 43, 806-810.	2.8	72
216	Obesity and suppressed B-type natriuretic peptide levels in heart failure. Journal of the American College of Cardiology, 2004, 43, 1590-1595.	2.8	445

#	ARTICLE	IF	CITATIONS
217	Working group 4: International medical graduates and the cardiology workforce. <i>Journal of the American College of Cardiology</i> , 2004, 44, 245-251.	2.8	17
218	Electronic home monitoring reduces medical resource utilization in chronic heart failure: a prospective investigation of the HomMed-sentry telemonitoring system. <i>Journal of Cardiac Failure</i> , 2004, 10, S110-S111.	1.7	4
219	Benefits of inpatient initiation of β^2 -blockers. <i>American Heart Journal</i> , 2004, 148, 944-950.	2.7	8
220	Exercise Capacity in Adult African-Americans Referred for Exercise Stress Testing. <i>Chest</i> , 2004, 126, 1962-1968.	0.8	47
221	White Coat Hypertension and Sleep Apnea. <i>Chest</i> , 2004, 125, 805-807.	0.8	5
222	Cardiac Troponin Levels in Heart Failure. <i>Cardiology in Review</i> , 2004, 12, 21-25.	1.4	40
223	Destination therapy in late-stage heart failure. <i>Coronary Artery Disease</i> , 2004, 15, 87-90.	0.7	3
224	Beta-Blocker Therapy and Severe Heart Failure: Myth or Reality?. <i>Congestive Heart Failure</i> , 2003, 9, 197-202.	2.0	5
225	Historical Vignettes in Heart Failure. <i>Congestive Heart Failure</i> , 2003, 9, 108-108.	2.0	1
226	Percutaneous Transluminal Septal Myocardial Ablation in the Management of Hypertrophic Obstructive Cardiomyopathy. <i>Congestive Heart Failure</i> , 2003, 9, 343-346.	2.0	0
227	Is all intimal proliferation created equal in cardiac allograft vasculopathy? The quantityâ€“quality paradox. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 118-123.	0.6	21
228	Treatment of hypertension for patients with diastolic dysfunction. <i>Current Opinion in Cardiology</i> , 2003, 18, 272-277.	1.8	2
229	The Conundrum of Sleep Breathing Disorders in Heart Failure. <i>Chest</i> , 2003, 123, 1332-1334.	0.8	4
230	Merrill Odom Hines, MD: The Right Fellow for the Job. <i>Ochsner Journal</i> , 2003, 5, 30-3.	1.1	0
231	Francis Earnest ("Duke") Lejeune, MD. <i>Ochsner Journal</i> , 2003, 5, 47-8.	1.1	1
232	Benzocaine induced methemoglobinemia: a potentially fatal complication of transesophageal echocardiography. <i>Ochsner Journal</i> , 2003, 5, 34-5.	1.1	3
233	Dean Holland Echols, MD: The Sixth Founder. <i>Ochsner Journal</i> , 2003, 5, 43-5.	1.1	2
234	The Copernicus journey. <i>American Journal of Cardiology</i> , 2002, 89, 783-784.	1.6	0

#	ARTICLE	IF	CITATIONS
235	Sir Christiaan Barnard: a personal reflection. American Journal of Cardiology, 2002, 89, 782-783.	1.6	0
236	Historical Vignettes in Heart Failure. Congestive Heart Failure, 2002, 8, 92-92.	2.0	0
237	Edward D. Frohlich, MD A Conversation About Hypertension: From Bedside to Bench and Return. Congestive Heart Failure, 2002, 8, 321-330.	2.0	2
238	Is heart failure with preserved systolic function an overlooked enigma?. Current Cardiology Reports, 2002, 4, 187-193.	2.9	5
239	Alton Ochsner, MD: Physician. Ochsner Journal, 2002, 4, 48-52.	1.1	10
240	The comprehensive management of anticoagulation: ochsner coumadin clinic. Ochsner Journal, 2002, 4, 37-40.	1.1	3
241	Guy Alvin Caldwell, MD: Physician and Administrator. Ochsner Journal, 2002, 4, 112-4.	1.1	3
242	Edgar burns. Ochsner Journal, 2002, 4, 180-2.	1.1	1
243	Curtis tyrone, MD. Ochsner Journal, 2002, 4, 245-6.	1.1	1
244	Treatment of heart failure according to William Stokes: The enchanted mercury. Journal of Cardiac Failure, 2001, 7, 277-282.	1.7	8
245	Desperate diseases, desperate measures: Tackling malignant hypertension in the 1950s. American Heart Journal, 2001, 142, 197-203.	2.7	15
246	Role of vascular remodeling in the pathogenesis of early transplant coronary artery disease: a multicenter prospective intravascular ultrasound study. Journal of Heart and Lung Transplantation, 2001, 20, 385-392.	0.6	55
247	SAFETY, TOLERABILITY, AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL-BASED FORMULATION OF CYCLOSPORINE???RESULTS AT 24 MONTHS AFTER TRANSPLANTATION1. Transplantation, 2001, 71, 70-78.	1.0	39
248	Historical perspectives on cardiac transplantation: the past as prologue to challenges for the 21st century. Current Opinion in Cardiology, 2001, 16, 118-123.	1.8	12
249	Valvular heart disease and pregnancy. Postgraduate Medicine, 2001, 110, 69-88.	2.0	8
250	Recent developments in microvascular angina. Current Atherosclerosis Reports, 2001, 3, 149-155.	4.8	4
251	Insights into ventricular repolarization abnormalities in cardiac allograft vasculopathy. American Journal of Cardiology, 2001, 87, 367-368.	1.6	15
252	From new orleans to buenos aires: my meeting with dr. renÃ© gerÃ³nimo favaloro. American Journal of Cardiology, 2001, 87, 672-673.	1.6	0

#	ARTICLE	IF	CITATIONS
253	Raison d'Être Behind ACE Inhibitors and AT1Receptor Combinations in Chronic Heart Failure: Chemical Nuances or Clinical Significance?. <i>Congestive Heart Failure</i> , 2001, 7, 101-104.	2.0	0
254	Historical Vignettes in Heart Failure. <i>Congestive Heart Failure</i> , 2001, 7, 111-111.	2.0	0
255	Nuggets, Pearls, and Vignettes of Master Heart Failure Clinicians. <i>Congestive Heart Failure</i> , 2001, 7, 245-249.	2.0	4
256	Difficult Cases in Heart Failure Marc A. Silver, MD Hector O. Ventura, MD Editors. Beneficial Effects of Aldosterone Blockade in Heart Failure. <i>Congestive Heart Failure</i> , 2000, 6, 115-117.	2.0	0
257	Impedance Cardiography: Noninvasive Measurement of Cardiac Stroke Volume and Thoracic Fluid Content. <i>Congestive Heart Failure</i> , 2000, 6, 56-59.	2.0	19
258	Impedance Cardiography: A Bridge Between Research and Clinical Practice in the Treatment of Heart Failure. <i>Congestive Heart Failure</i> , 2000, 6, 94-102.	2.0	13
259	Bridge to A-V Blockade in Severe Heart Failure: The Use of Phosphodiesterase Inhibitors. <i>Congestive Heart Failure</i> , 2000, 6, 164-166.	2.0	2
260	Bridging Patients to Cardiac Transplantation. <i>Congestive Heart Failure</i> , 2000, 6, 238-243.	2.0	14
261	Ventricular Resynchronization in Refractory Heart Failure. <i>Congestive Heart Failure</i> , 2000, 6, 333-336.	2.0	0
262	The AHF SCENE II Preceptorship Program: Rationale and Design of an Educational Program to Optimize Management of Advanced Heart Failure. <i>Congestive Heart Failure</i> , 2000, 6, 319-324.	2.0	1
263	Robert James Graves and the cardiovascular responses to postural changes in heart failure. <i>American Journal of Cardiology</i> , 2000, 85, 1503-1506.	1.6	5
264	Rudolph virchow and cellular pathology. <i>Clinical Cardiology</i> , 2000, 23, 550-552.	1.8	6
265	Giovanni Battista Morgagni and the foundation of modern medicine. <i>Clinical Cardiology</i> , 2000, 23, 792-794.	1.8	16
266	Study of Arterial and Autonomic Effects of Cyclosporine in Humans. <i>Hypertension</i> , 2000, 35, 1258-1263.	2.7	30
267	The independent effects of left ventricular ejection fraction on short-term outcomes and resource utilization following hospitalization for heart failure. <i>Clinical Cardiology</i> , 1999, 22, 184-190.	1.8	38
268	The prognostic implications of outpatient diuretic dose in heart failure. <i>International Journal of Cardiology</i> , 1999, 71, 219-225.	1.7	24
269	Treatment of the hypertensive patient with microvascular angina. <i>Current Opinion in Cardiology</i> , 1999, 14, 370.	1.8	6
270	Colles-Stokes Contributions to the Concept of Heart Failure. <i>American Journal of Cardiology</i> , 1998, 81, 1470-1473.	1.6	9

#	ARTICLE	IF	CITATIONS
271	Effects of caregiver specialty on cost and clinical outcomes following hospitalization for heart failure. <i>American Journal of Cardiology</i> , 1998, 82, 82-85.	1.6	119
272	Coronary stenting in cardiac allograft vasculopathy. <i>Journal of the American College of Cardiology</i> , 1998, 32, 1636-1640.	2.8	44
273	Mitral inflow and pulmonary venous Doppler measurements do not predict pulmonary capillary wedge pressure in heart transplant recipients. <i>American Heart Journal</i> , 1998, 135, 641-646.	2.7	9
274	Photopheresis for the Prevention of Rejection in Cardiac Transplantation. <i>New England Journal of Medicine</i> , 1998, 339, 1744-1751.	27.0	304
275	Home Inotropic Therapy in Advanced Heart Failure. <i>Chest</i> , 1997, 112, 1298-1303.	0.8	50
276	Searching for Peter Pan. <i>Postgraduate Medicine</i> , 1997, 101, 22-24.	2.0	0
277	CYCLOSPORINE-INDUCED HYPERTENSION IN CARDIAC TRANSPLANTATION. <i>Medical Clinics of North America</i> , 1997, 81, 1347-1357.	2.5	26
278	Implications for the vascular surgeon with prolonged (3 to 89 days) intraaortic balloon pump counterpulsation. <i>Journal of Vascular Surgery</i> , 1997, 26, 511-516.	1.1	27
279	Allograft aortopathy: An in vivo study of donor aorta involvement in cardiac allograft vasculopathy. <i>American Heart Journal</i> , 1997, 133, 698-702.	2.7	14
280	Heterogeneity of Cardiac Allograft Vasculopathy: Clinical Insights From Coronary Angioscopy. <i>Journal of the American College of Cardiology</i> , 1997, 29, 1339-1344.	2.8	31
281	The unique management of refractory advanced systolic heart failure. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 1997, 26, 280-288.	1.6	1
282	Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. <i>American Journal of Cardiology</i> , 1997, 80, 61-64.	1.6	82
283	Management of Cardiac Allograft Vasculopathy by Transmyocardial Laser Revascularization. <i>American Journal of Cardiology</i> , 1997, 80, 224-225.	1.6	15
284	Lipid-Lowering Therapy and Long-Term Survival in Heart Transplantation. <i>American Journal of Cardiology</i> , 1997, 80, 802-805.	1.6	24
285	Usefulness of Peak Oxygen Consumption in Predicting Outcome of Heart Failure in Women Versus Men. <i>American Journal of Cardiology</i> , 1997, 80, 1236-1238.	1.6	37
286	The Incidence, Morbidity, and Mortality of Surgical Procedures After Orthotopic Heart Transplantation. <i>Annals of Surgery</i> , 1997, 225, 686-694.	4.2	39
287	Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation Results of a prospective, randomized multicenter trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 1707-1712.	2.8	61
288	Modulation of tumor necrosis factor $\hat{\pm}$ in advanced heart failure with cachexia is associated with anabolic effects. <i>Journal of the American College of Cardiology</i> , 1996, 27, 70-71.	2.8	2

#	ARTICLE	IF	CITATIONS
289	Treatment of hyperlipidemia after heart transplantation and rationale for the heart transplant lipid registry. American Journal of Cardiology, 1996, 78, 532-535.	1.6	18
290	On-Line Myocardial Tissue Characterization with a New Commercially Produced Software. Echocardiography, 1996, 13, 271-279.	0.9	2
291	The Clinical Relevance of Circulating Tumor Necrosis Factor- α in Acute Decompensated Chronic Heart Failure Without Cachexia. Chest, 1996, 110, 992-995.	0.8	71
292	An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. American Journal of Cardiology, 1995, 75, 853-854.	1.6	102
293	Cardiac allograft vasculopathy: Current concepts. American Heart Journal, 1995, 129, 791-799.	2.7	112
294	Predictive model to assess risk for cardiac allograft vasculopathy: An intravascular ultrasound study. Journal of the American College of Cardiology, 1995, 26, 1537-1544.	2.8	84
295	Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. American Journal of Cardiology, 1994, 74, 1042-1046.	1.6	87
296	Love Is the Best Doctor. Annals of Internal Medicine, 1994, 120, 890.	3.9	0
297	Increased oxygen delivery reduced morbidity and mortality in high-risk surgery. ACP Journal Club, 1994, 120, 76.	0.1	0
298	Percutaneous Coronary Angioscopy: Applications in Interventional Cardiology. Journal of Interventional Cardiology, 1993, 6, 61-68.	1.2	13
299	Assessment of intracoronary morphology in cardiac transplant recipients by angioscopy and intravascular ultrasound. American Journal of Cardiology, 1993, 72, 805-809.	1.6	30
300	De novo appearance of a myocardial bridge in heart transplant: Assessment by intravascular ultrasonography, Doppler, and angioscopy. American Heart Journal, 1993, 126, 453-456.	2.7	22
301	Valvular Regurgitation and Right-sided Cardiac Pressures in Heart Transplant Recipients by Complete Doppler and Color Flow Evaluation. Chest, 1993, 104, 82-87.	0.8	48
302	Induction Immunosuppression with the Monoclonal Antibody OKT3 After Cardiac Transplantation. American Journal of the Medical Sciences, 1993, 306, 16-19.	1.1	4
303	Going home. Postgraduate Medicine, 1993, 93, 159-160.	2.0	3
304	Cardiac Transplantation: Clinical Aspects of Recipient Selection. Medical Clinics of North America, 1992, 76, 1196-1206.	2.5	1
305	Current issues in advanced heart failure. Medical Clinics of North America, 1992, 76, 1057-1082.	2.5	1
306	Left ventricular hypertrophy. Postgraduate Medicine, 1992, 91, 131-143.	2.0	54

#	ARTICLE	IF	CITATIONS
307	THE SIGNAL-AVERAGED ELECTROCARDIOGRAM IN CARDIAC TRANSPLANTATION. <i>Transplantation</i> , 1992, 53, 124-127.	1.0	14
308	Cardiac adaptation to obesity and hypertension after heart transplantation. <i>Journal of the American College of Cardiology</i> , 1992, 19, 55-59.	2.8	21
309	Regression of Increased Left Ventricular Mass by Antihypertensives. <i>Drugs</i> , 1991, 42, 945-961.	10.9	40
310	Arterial hypertension after orthotopic cardiac transplantation. <i>Journal of the American College of Cardiology</i> , 1990, 15, 1102-1103.	2.8	12
311	Left Atrial Abnormalities Indicating Diastolic Ventricular Dysfunction in Cardiopathy of Obesity. <i>Chest</i> , 1987, 92, 1042-1046.	0.8	83
312	Heparin-Induced Hyperkalemia. <i>Southern Medical Journal</i> , 1987, 80, 1450-1451.	0.7	17
313	Osler's Maneuver and Pseudohypertension. <i>New England Journal of Medicine</i> , 1985, 312, 1548-1551.	27.0	213
314	Immediate hemodynamic effects of urapidil in patients with essential hypertension. <i>American Journal of Cardiology</i> , 1985, 55, 722-725.	1.6	22
315	Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. <i>American Journal of Cardiology</i> , 1985, 55, 1023-1026.	1.6	97
316	Hypertension and sudden death. <i>American Journal of Medicine</i> , 1984, 77, 18-22.	1.5	554
317	Impaired systemic arterial compliance in borderline hypertension. <i>American Heart Journal</i> , 1984, 108, 132-136.	2.7	92
318	Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. <i>American Journal of Cardiology</i> , 1984, 53, 105-108.	1.6	236
319	Diurnal Variation of Blood Pressure in Elderly Patients with Essential Hypertension. <i>Journal of the American Geriatrics Society</i> , 1984, 32, 896-899.	2.6	153
320	Immediate hemodynamic effects of a new calcium-channel blocking agent (nitrendipine) in essential hypertension. <i>American Journal of Cardiology</i> , 1983, 51, 783-786.	1.6	68
321	Racial differences in cardiac adaptation to essential hypertension determined by echocardiography indexes. <i>Journal of the American College of Cardiology</i> , 1983, 1, 1348-1351.	2.8	141
322	Diurnal variations of cardiac rhythm, arterial pressure, and urinary catecholamines in borderline and established essential hypertension. <i>American Heart Journal</i> , 1982, 104, 109-114.	2.7	76
323	Left ventricular adaptation to obesity. <i>American Journal of Cardiology</i> , 1982, 49, 977.	1.6	7
324	Arterial Compliance in Systolic Hypertension. <i>Clinical and Experimental Hypertension</i> , 1982, 4, 1037-1044.	0.3	18